Uptake and release of dexamethasone phosphate from silicone hydrogel and group I, II, and IV hydrogel contact lenses

Eye and Contact Lens

Volumn 35, Issue 5, 2009, Pages 260-267

  Boone, Adrienne ^a   Hui, Alex ^a   Jones, Lyndon ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Dexamethasone; Silicone hydrogel; Contact lens; Drug delivery; Bandage lens

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; SILICONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTACT LENS; CONTROLLED STUDY; DRUG RELEASE; DRUG UPTAKE; KINETICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTI-INFLAMMATORY AGENTS; CONTACT LENSES, HYDROPHILIC; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEL; SILICONES; SPECTROPHOTOMETRY; TIME FACTORS;

EID: 70349138441     PISSN: 15422321     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICL.0b013e3181b26c49     Document Type: Article

References (59)

1. Karlgard CC, Jones LW, Moresoli C. Survey of bandage lens use in North America, October-December 2002. Eye Contact Lens 2004;30:25-30.
2. Mely R. Therapeutic and cosmetic indications of lotrafilcon a silicone hydrogel extended-wear lenses. Ophthalmologica 2004;218 (suppl 1):29- 38; discussion 45-46.
3. Morrison R, Shovlin JP. A review of the use of bandage lenses. Metab Pediatr Syst Ophthalmol 1982;6:117-121.
4. Tuli SS, Schultz GS, Downer DM. Science and strategy for preventing and managing corneal ulceration. Ocul Surf 2007;5:23-39.
5. Wheeler JC, Woods JA, Cox MJ, et al. Evolution of hydrogel polymers as contact lenses, surface coatings, dressings, and drug delivery systems. J Long Term Eff Med Implants 1996;6:207-217.
6. Sedlacek J. [Possibility of the application of ophthalmic drugs with the use of gel contact lenses]. Cesk Oftalmol 1965;21:509-512.
7. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993;37:435-456.
8. Tian X, Iwatsu M, Sado K, et al. Studies on the uptake and release of fluoroquinolones by disposable contact lenses. CLAO J 2001;27:216-220
9. Lesher GA, Gunderson GG. Continuous drug delivery through the use of disposable contact lenses. Optom Vis Sci 1993;70:1012-1018.
10. Hillman JS, Marsters JB, Broad A. Pilocarpine delivery by hydrophilic lens in the management of acute glaucoma. Trans Ophthalmol Soc U K 1975;95:79-84.
11. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004;45:2342-2347.
12. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: A potential ophthalmic drug delivery vehicle. Int J Pharm 2005;292:95-117.
13. Gulsen D, Li CC, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr Eye Res 2005;30:1071-1080.
14. Uchida R, Sato T, Tanigawa H, et al. Azulene incorporation and release by hydrogel containing methacrylamide propyltrimenthylammonium chloride, and its application to soft contact lens. J Control Release 2003;92: 259-264.
15. Hiratani H, Alvarez-Lorenzo C. Timolol uptake and release by imprinted soft contact lenses made of N, N-diethylacrylamide and methacrylic acid. J Control Release 2002;83:223-230.
16. Xinming L, Yingde C, Lloyd AW, et al. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: A review. Cont Lens Anterior Eye 2008;31:57-64.
17. Chapman JM, Cheeks L, Green K. Interactions of benzalkonium chloride with soft and hard contact lenses. Arch Ophthalmol 1990;108:244-246.
18. Gasset AR. Benzalkonium chloride toxicity to the human cornea. Am J Ophthalmol 1977;84:169-171.
19. Lemp MA. Bandage lenses and the use of topical solutions containing preservatives. Ann Ophthalmol 1978;10:1319-1321.
20. Richardson NE, Davies DJ, Meakin BJ, et al. The interaction of preservatives with polyhydroxyethylmethacrylate (polyHEMA). J Pharm Pharmacol 1978;30:469-475.
21. Dracopoulos A, Dixon DG, Jones LW, et al. In vitro assessment of medical device toxicity: Interactions of benzalkonium chloride with silicone-containing and p-hema-containing hydrogel contact lens materials. Eye Contact Lens 2007;33:26-37.
22. Li C-C, Chauhan A. Modeling ophthalmic drug delivery by soaked contact lenses. Ind Eng Chem Res 2006;45:3718-3734.
23. Hillman JS. Management of acute glaucoma with pilocarpine-soaked hydrophilic lens. Br J Ophthalmol 1974;58:674-679.
24. McNamara NA, Polse KA, Brand RJ, et al. Tear mixing under a soft contact lens: Effects of lens diameter. Am J Ophthalmol 1999;127:659-665.
25. Brennan NA, Coles ML. Extended wear in perspective. Optom Vis Sci 1997;74:609-623.
26. Holden BA. The Glenn A. Fry award lecture 1988: The ocular response to contact lens wear. Optom Vis Sci 1989;66:717-733.
27. Holden BA, Mertz GW. Critical oxygen levels to avoid corneal edema for daily and extended wear contact lenses. Invest Ophthalmol Vis Sci 1984; 25:1161-1167.
28. Schein OD, Glynn RJ, Poggio EC, et al. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med 1989;321:773-778.
29. Tighe B. Silicone hydrogel materials-how do they work? In: Sweeney D, ed. Silicone Hydrogels: The Rebirth of Continuous Wear Contact Lenses, Oxford, UK, Butterworth-Heinemann, 2000, pp 1-21.
30. Efron N, Morgan PB, Cameron ID, et al. Oxygen permeability and water content of silicone hydrogel contact lens materials. Optom Vis Sci 2007; 84:328-337.
31. Jones L, Subbaraman LN, Rogers R, et al. Surface treatment, wetting and modulus of silicone hydrogels. Optician 2006;232:28-34.
32. Morgan PB, Woods C, Tranoudis I, et al. International contact lens prescribing in 2008. Contact Lens Spectrum 2009;24:28-32.
33. Woods CA, Jones DA, Jones LW, et al. A seven year survey of the contact lens prescribing habits of Canadian optometrists. Optom Vis Sci 2007;84: 505-510.
34. Montero J, Sparholt J, Mely R, et al. Retrospective case series of therapeutic applications of lotrafilcon a silicone hydrogel soft contact lenses. Eye Contact Lens 2003;29:72-75.
35. Lim L, Tan DT, Chan WK. Therapeutic use of Bausch & Lomb PureVision contact lenses. CLAO J 2001;27:179-185.
36. Foulks GN, Harvey T, Raj CV. Therapeutic contact lenses: The role of high-Dk lenses. Ophthalmol Clin North Am 2003;16:455-461.
37. Kanpolat A, Ucakhan OO. Therapeutic use of Focus Night & Day contact lenses. Cornea 2003;22:726-734.
38. Rubinstein MP. Applications of contact lens devices in the management of corneal disease. Eye 2003;17:872-876.
39. Ozkurt Y, Rodop O, Oral Y, Comez A, et al. Therapeutic applications of lotrafilcon a silicone hydrogel soft contact lenses. Eye Contact Lens 2005;31:268-269.
40. Bendoriene J, Vogt U. Therapeutic use of silicone hydrogel contact lenses in children. Eye Contact Lens 2006;32:104-108.
41. Arora R, Jain S, Monga S, et al. Efficacy of continuous wear PureVision contact lenses for therapeutic use. Cont Lens Anterior Eye 2004;27:39-43.
42. Karlgard CC, Jones LW, Moresoli C. Ciprofloxacin interaction with silicon-based and conventional hydrogel contact lenses. Eye Contact Lens 2003;29:83-89.
43. Karlgard CC, Wong NS, Jones LW, et al. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int J Pharm 2003;257:141-151.
44. Tighe B. Contact lens materials. In: Phillips A, Speedwell L, eds. Contact Lenses. Edinburgh, UK, Butterworth-Heinemann, 2006, pp 59-78.
45. Russo S, Papa V, Di Bella A, et al. Dexamethasone-netilmicin: A new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. Eye 2007;21:58-64.
46. Heyrman TP, McDermott ML, Ubels JL, et al. Drug uptake and release by a hydrogel intraocular lens and the human crystalline lens. J Cataract Refract Surg 1989;15:169-175.
47. Chapman JM, Cheeks L, Green K. Drug interaction with intraocular lenses of different materials. J Cataract Refract Surg 1992;18:456-459.
48. Kim J, Chauhan A. Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. Int J Pharm 2008;353:205-222.
49. Hui A, Boone A, Jones L. Uptake and release of ciprofloxacin-HCl from conventional and silicone hydrogel contact lens materials. Eye Contact Lens 2008;34:266-271.
50. Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med 2005;34:589-595.
51. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician 1998;58:443-450.
52. Seo KY, Chung SH, Lee JH, et al. Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone. Cornea 2007;26:709-714.
53. Bourcier T, Forgez P, Borderie V, et al. Regulation of human corneal epithelial cell proliferation and apoptosis by dexamethasone. Invest Ophthalmol Vis Sci 2000;41:4133-4141.
54. Djalilian AR, Nagineni CN, Mahesh SP, et al. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea 2006;25:709-714.
55. Bourcier T, Borderie V, Forgez P, et al. In vitro effects of dexamethasone on human corneal keratocytes. Invest Ophthalmol Vis Sci 1999;40:1061-1070. (Pubitemid 29211443)
56. Mishima S, Gasset A, Klyce SD Jr, et al. Determination of tear volume and tear flow. Invest Ophthalmol 1966;5:264-276.
57. Wang J, Simmons P, Aquavella J, et al. Dynamic distribution of artificial tears on the ocular surface. Arch Ophthalmol 2008;126:619-625.
58. Sendrowski DP, Jaanus SD, Semes LP, et al. Anti-Inflammatory Drugs. In: Clinical Ocular Pharmacology, Bartlett JD, Jaanus SD, eds. St. Louis, MO, Butterworth Heinemann, 2008, pp 221-244.
59. Subbaraman LN, Glasier MA, Senchyna M, et al. Kinetics of in vitro lysozyme deposition on silicone hydrogel, PMMA, and FDA groups I, II, and IV contact lens materials. Curr Eye Res 2006;31:787-796.